Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.
Back
Whole Genome Sequencing Identifies Myeloma Precursor Conditions
C.Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their study exploring the utility of whole-genome sequencing in patients with monoclonal gammopathy of uncertain significance and smoldering myeloma to see whether they could identify genomic signatures capable of predicting progression to multiple myeloma.
Whole Genome Sequencing Identifies Myeloma Precursor Conditions
Episodes
All
All
Whole-genome sequencing has the potential to accurately differentiate between stable and progressive precursor conditions to multiple myeloma in low disease burden clinical states and the use of this technology in the clinic may result in a significant shift in the management of these patients.
Ola Landgren, MD, PhD, discusses the rationale behind examining whole-genome sequencing in smoldering myeloma.
Francesco Maura, MD, discusses the significance of studying genomic defining events in patients with multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
4
Dana-Farber Researchers Identify CDK8 as a Potential Therapeutic Target for Alveolar Rhabdomyosarcoma
5